

Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
MRNA | NASDAQ | USD | Real-time | |
MRNA | Mexico | MXN | Delayed | |
0QF | Frankfurt | EUR | Delayed | |
0QF | TradeGate | EUR | Delayed | |
MRNA_KZ | KASE | USD | Delayed | |
MRNA | Lima | USD | Delayed |
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Stephane Bancel | 49 | 2011 | CEO & Director |
Stephen A. Berenson | 61 | 2017 | Independent Non Executive Director |
Robert S. Langer | 73 | 2010 | Independent Non Executive Director & Member of Scientific Advisory Board |
Jack W. Szostak | - | 2014 | Chairman of Scientific Advisory Board |
Ron Eydelloth | - | - | Member of Scientific Advisory Board |
Paula T. Hammond | 58 | - | Member of Scientific Advisory Board |
Noubar B. Afeyan | 59 | 2010 | Co-Founder, Independent Non Executive Chairman & Member of Technology Advisory Board |
Elizabeth Edith Tallett | 72 | 2020 | Independent Director |
Scott A. Canute | 61 | 2014 | Member of Technology Advisory Board |
Paul L. Sagan | 63 | 2018 | Independent Non Executive Director |
Ulrich H. von Andrian-Werburg | - | - | Member of Scientific Advisory Board |
Fred E. Regnier | - | 2014 | Member of Technology Advisory Board |
Michael Diamond | - | - | Member of Scientific Advisory Board |
Richard C. Willson | - | 2014 | Member of Technology Advisory Board |
Ralph Weissleder | - | - | Member of Scientific Advisory Board |
John G. Aunins | 61 | 2014 | Member of Technology Advisory Board |
James R. Swartz | - | 2014 | Member of Technology Advisory Board |
Francois Nader | 65 | 2019 | Independent Non Executive Director |
Sandra J. Horning | 73 | 2020 | Independent Director |
Elizabeth G. Nabel | 70 | 2021 | Independent Director |
Rachel Green | - | - | Member of Scientific Advisory Board |
Melissa J. Moore | - | 2016 | Chief Scientific Officer & Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review